Skip to main content

Table 3 Highly prevalent QT interval prolonging drugs (≥5)a in various types of cancer

From: Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study

QT drugs TdP riskb QT drugs: n (%)c
Breast cancer
 Ondansetron Known risk of TdP 54 (5.4)
 Ciprofloxacin Known risk of TdP 32 (3.2)
 Tropisetron Possible risk of TdP 20 (2)
 Metoclopramide Conditional risk of TdP 18 (1.8)
 Omeprazole Conditional risk of TdP 8 (0.8)
 Esomeprazole Conditional risk of TdP 6 (0.6)
Gastrointestinal cancer
 Ondansetron Known risk of TdP 46 (4.6)
 Capecitabine Possible risk of TdP 25 (2.5)
 Metoclopramide Conditional risk of TdP 21 (2.1)
 Oxaliplatin Known risk of TdP 20 (2)
 Tropisetron Possible risk of TdP 17 (1.7)
 Omeprazole Conditional risk of TdP 17 (1.7)
 Ciprofloxacin Known risk of TdP 13 (1.3)
 Esomeprazole Conditional risk of TdP 7 (0.7)
Non hodgkin lymphoma
 Ondansetron Known risk of TdP 39 (3.9)
 Tropisetron Possible risk of TdP 33 (3.3)
 Metoclopramide Conditional risk of TdP 25 (2.5)
 Esomeprazole Conditional risk of TdP 16 (1.6)
 Omeprazole Conditional risk of TdP 14 (1.4)
 Ciprofloxacin Known risk of TdP 5 (0.5)
Gynecologic cancer
 Ondansetron Known risk of TdP 25 (2.5)
 Tropisetron Possible risk of TdP 9 (0.9)
 Ciprofloxacin Known risk of TdP 8 (0.8)
 Metoclopramide Conditional risk of TdP 7 (0.7)
 Omeprazole Conditional risk of TdP 7 (0.7)
 Esomeprazole Conditional risk of TdP 5 (0.5)
Genitourinary cancer
 Ondansetron Known risk of TdP 18 (1.8)
 Esomeprazole Conditional risk of TdP 5 (0.5)
Acute lymphoblastic leukemia
 Metoclopramide Conditional risk of TdP 16 (1.6)
 Omeprazole Conditional risk of TdP 16 (1.6)
 Ondansetron Known risk of TdP 7 (0.7)
 Metronidazole Conditional risk of TdP 6 (0.6)
Chronic lymphocytic leukemia
 Tropisetron Possible risk of TdP 11 (1.1)
 Metoclopramide Conditional risk of TdP 8 (0.8)
Hodgkin lymphoma
 Ondansetron Known risk of TdP 9 (0.9)
 Metoclopramide Conditional risk of TdP 8 (0.8)
Musculoskeletal cancer
 Ondansetron Known risk of TdP 9 (0.9)
 Metoclopramide Conditional risk of TdP 7 (0.7)
 Tropisetron Possible risk of TdP 6 (0.6)
Colorectal carcinoma
 Capecitabine Possible risk of TdP 8 (0.8)
 Oxaliplatin Known risk of TdP 7 (0.7)
 Ondansetron Known risk of TdP 5 (0.5)
Acute mylogenous leukemia
 Omeprazole Conditional risk of TdP 7 (0.7)
 Metoclopramide Conditional risk of TdP 5 (0.5)
Lung cancer
 Ondansetron Known risk of TdP 6 (0.6)
Neurological cancer
 Ondansetron Known risk of TdP 6 (0.6)
Adenocarcinoma
 Metoclopramide Conditional risk of TdP 5 (0.5)
  1. AZCERT Arizona Center for Education and Research on Therapeutics, TdP torsades de pointes
  2. aRemaining results have been mentioned in Additional file 1: Table S1
  3. bTdP risk was based on the AZCERT QT drugs lists
  4. cPercentage calculated in total number of QT interval prolonging drugs i.e., 993